Brought to you by 
Third Wave raises $48mm through private placement
05 Mar 2013
Executive Summary
Third Wave, which develops technologies for DNA and RNA analysis, received $48mm from a private financing. BB Biotech led the round, which also attracted returning investors Wellcome Trust; Schroder Ventures, Burrill Agbio Capital Fund, UK Medical Ventures, Venture Investors of Wisconsin, and Wisconsin Alumni Research Foundation. New investors include Janus Capital, Putnam Investments, American Express, Scudder Funds, INVESCO Funds Group, Tisch Family Interests, Essex, Galleon Investments, CIBC Capital Partners, and Jennison Capital.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
-
Drug Discovery Tools
- Genomics-Proteomics
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Third Wave raises $48mm through private placement
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice